ShieldM.J.Diclofenac/misoprostol: novel findings and their clinical potential.J Rheumatol Suppl 1998; 51: 31–41.
4.
BrockbankJ., GladmanD.Diagnosis and management of psoriatic arthritis.Drugs2002; 62(17): 2447–57.
5.
Abu-ShakraLongterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome.J Rheumatol1995; 22(2): 241–5.
6.
BarnhartK., CoutifarisC., EspositoM.The pharmacology of methotrexate.Expert Opin Pharmacother2001; 2(3): 409–17.
7.
WeinblattMESulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials.J Rheumatol1999; 26(10): 2123–30.
8.
CleggD.O., RedaD.J., MejiasE.Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study.Arthritis Rheum1996; 39(12): 2013–20.
9.
KaltwasserP., NashP., GladmanD.Efficacy and Safety of Leflunomide in the treatment of psoriatic arthritis: results from the TOPAS study. Poster Presentation, 66th Annual Meeting of the American College of Rheumatology, New Orleans, LA, 2002.
10.
CunnaneG., MadiganA., MurphyE.The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis.Rheumatology2001; 40: 62–9.
11.
WolfR., RuoccoV.Triggered psoriasis.Adv Exp Med Biol1999; 455: 221–5.
12.
PartschG.Highly increased levels of tumor necrosis factor-alpha and other inflammatory cytokines in psoriatic arthritis synovial fluid.J Rheumatol1997; 24: 518.
MoorelandL.W.Etanercept therapy in rheumatoid arthritis.Ann Intern Med1999; 130: 478.
15.
LovellD.J.Etanercept in children with polyarticular juvenile rheumatoid arthritis.N Engl J Med2000; 342: 763.
16.
MeaseP.J., GoffeB.S., MetzJEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial.Lancet2000; 356: 385–90.
17.
WeinblattM.E.A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.N Engl J Med1999; 340: 253.
18.
AnandarajahA.P., RitchlinC.T.Etanercept in psoriatic arthritis.Expert Opin Biol Ther2003; 3(1): 169–77.
19.
Van denB.F., KruitofE., BaetenD., de KeyserF., MielantsH., VeysE.M.Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.Ann Rheum Dis2000; 59: 428–33.
20.
AntoniC.Ann Rheum Dis2003; 62(Suppl 1).
21.
KraanM.C., van KuijkA.W., DinantHJAlefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis.Arthritis Rheum2002; 46: 2776–84.
